Volume | 3,166,035 |
|
|||||
News | - | ||||||
Day High | 1.81 | Low High |
|||||
Day Low | 1.66 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Perspective Therapeutics Inc | CATX | AMEX | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.80 | 1.66 | 1.81 | 1.80 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
10,666 | 3,166,035 | $ 1.72 | $ 5,457,978 | - | 0.205 - 1.90 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:59:08 | 90 | $ 1.715 | USD |
Perspective Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
106.62M | 280.57M | - | 1.43M | -46.51M | -0.17 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Perspective Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CATX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.75 | 1.90 | 1.66 | 1.80 | 4,410,165 | -0.035 | -2.00% |
1 Month | 1.40 | 1.90 | 1.29 | 1.64 | 4,759,475 | 0.315 | 22.50% |
3 Months | 0.86 | 1.90 | 0.805 | 1.40 | 4,401,964 | 0.855 | 99.42% |
6 Months | 0.27 | 1.90 | 0.2201 | 1.17 | 2,917,267 | 1.45 | 535.19% |
1 Year | 0.6481 | 1.90 | 0.205 | 1.02 | 1,779,695 | 1.07 | 164.62% |
3 Years | 0.3763 | 1.90 | 0.205 | 0.9895874 | 1,580,134 | 1.34 | 355.75% |
5 Years | 0.3763 | 1.90 | 0.205 | 0.9895874 | 1,580,134 | 1.34 | 355.75% |
Perspective Therapeutics Description
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Company¿s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions. |